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Signaling networks downstream of receptor tyrosine kinases are among the 
most extensively studied biological networks, but new approaches are needed to 
elucidate causal relationships between network components and understand 
how such relationships are influenced by biological context and disease. Here, 
we investigate the context-specificity of signaling networks within a causal 
conceptual framework, using reverse-phase protein array time-course assays 
and network analysis approaches. We focus on a well-defined set of signaling 
proteins profiled under inhibition with five kinase inhibitors in 32 contexts—
four breast cancer cell lines (MCF7, UACC812, BT20, and BT549) under eight 
stimulus conditions. The data, spanning multiple pathways and comprising 
~70,000 phosphoprotein and ~260,000 protein measurements, provide a 
wealth of testable, context-specific hypotheses, several of which we 
experimentally validate. Furthermore, the data provide a unique resource for 
computational methods development, permitting empirical assessment of causal 
network learning in a complex, mammalian setting.  
 
Introduction 
The complexity of mammalian receptor tyrosine kinase (RTK) signaling 
continues to pose challenges for the understanding of physiological processes 
and aberrations that are relevant to disease. Networks, comprising nodes and 
linking directed edges, are widely used to summarize and reason about signaling. 
Obviously, signaling systems depend on the concentration and localization of 
their component molecules, so signaling events may be influenced by genetic and 
epigenetic context (Saez-Rodriguez et al., 2011; Good et al., 2009; Zalatan et al., 
2012). In disease biology, and cancer in particular, an improved understanding 
of signaling in specific contexts may have implications for precision medicine by 
helping to explain variation in disease phenotypes or therapeutic response. 
 
Genomic heterogeneity in disease has been well studied, notably in cancer, and 
heterogeneity is also manifested at the level of differential expression of 
components of signaling pathways downstream of RTKs (Akbani et al., 2014; 
Gerlinger and Swanton, 2010; Nickel et al., 2012; Szerlip et al., 2012). However, 
 3 
 
differences in average protein abundance (as captured in differential expression 
or gene set analyses) are conceptually distinct from differences in the edge 
structure of signaling networks, with the latter implying a change in the ability of 
nodes to causally influence each other. Causal relationships are also 
fundamentally distinct from statistical correlations: if there is a causal edge from 
node A to node B, then the abundance of B may be changed by inhibition of A, but 
A and B can be correlated with no causal edge linking them (see below for an 
illustrative example). For this reason, standard concepts from multivariate 
statistics (that in turn underpin many network analyses in bioinformatics) may 
not be sufficient for causal analyses (Pearl, 2009).  
 
Canonical signaling pathways and networks (as described for example in 
textbooks and online resources) typically summarize evidence from multiple 
experiments, conducted in different cell types and growth conditions and 
therefore such networks are not specific to a particular context. Many well-
known links in such networks most likely hold widely and so canonical networks 
remain a valuable source of insights. However, if causal signaling depends on 
context then using canonical networks alone will neglect context-specific 
changes, with implications for reasoning, modeling and prediction. A large 
literature has focused on the question of inferring molecular networks from data 
(see e.g. De Smet and Marchal, 2010 and Marbach et al., 2010 for reviews). The 
potential for molecular networks to depend on context has motivated efforts to 
tailor network models in a data-driven manner (Marbach et al., 2016; Petsalaki 
et al., 2015; Will and Helms, 2016). Our approach is in this vein but with an 
emphasis on interventional data and a principled causal framework. Unbiased 
“interactome” approaches (e.g. Rolland et al., 2014) expand our view of the space 
of possible signaling interactions. However, due to the nature of genetic, 
epigenetic and environmental influences, such approaches cannot in general 
identify signaling events specific to biological context, e.g. specific to a certain 
cell type under defined conditions.  
 
We study context-specific signaling using human cancer cell lines. The data span 
32 contexts each defined by the combination of (epi)genetics (breast cancer cell 
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lines MCF7, UACC812, BT20 and BT549) and stimuli. In each of the 32 (cell line, 
stimulus) contexts, we carried out time-course experiments using kinase 
inhibitors as interventions (note that as used here the inhibitors do not 
contribute to defining the context). Reverse-phase protein arrays (RPPA; Tibes et 
al. 2006) were then used to interrogate signaling downstream of RTKs. We used 
more than 150 high-quality antibodies targeting mainly total and 
phosphorylated proteins (see Table S1). 
 
The inhibitors applied in each context allowed elucidation of context-specific 
causal influences between inhibited and downstream phosphoproteins. The 
extent of context-specificity seen can be summarized as follows: on average, 
across all kinase inhibitors and pairs of contexts in the study, approximately 1 in 
5 phosphoproteins show changes in abundance under inhibition in one context 
that are not seen in the other. We also modeled the data using recently 
developed methods rooted in probabilistic graphical models to reconstruct 
context-specific networks intended to capture causal interplay between all 
measured phosphoproteins (and not just interplay related to inhibited nodes).  
 
Thus, we show that causal signaling networks depend on context, with the 
pattern of changes under inhibition dependent on biological background. This is 
supported by independent validation experiments. Furthermore, we advance a 
conceptual view of signaling networks as causal networks (Pearl, 2009). In 
addition, this paper adds to available resources in two ways. First, the data we 
present acts as a valuable data resource, spanning all combinations of context, 
inhibitor and time, and allowing for a very wide range of analyses, including, but 
not limited to, analyses of the kind presented here. The data complement 
available patient datasets (see e.g. Akbani et al., 2014) by providing 
interventional readouts under defined conditions and provide a wealth of 
testable hypotheses regarding potentially novel and context-specific signaling 
links. Second, the data serve as a resource for computational biology 
benchmarking. Network reconstruction has long been a core topic in 
computational biology but performance with respect to learning of causal links 
has mainly been benchmarked using simulated data that may not adequately 
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reflect the challenges of real data and relevant biology. A previous study 
established a small, five node synthetic network in yeast that was valuable to the 
computational biology community as it provided a gold-standard network in a 
biological model (Cantone et al., 2009). The design of our experiments allows for 
systematic testing of causal network learning in a complex mammalian setting 
and provides a unique resource for development of computational biology 
methods. The data presented here were used in the recent HPN-DREAM 
(Heritage Provider Network – Dialogue for Reverse Engineering Assessment and 
Methods) network inference challenge. The challenge focused on causal 
networks and the data were used to score more than 2000 submitted networks ( 





Causal molecular networks and context-specificity 
We first define causal molecular networks at a conceptual level. Consider a 
specific cell line grown under defined conditions. We refer to the complete 
biological setting (including genetic/epigenetic background and 
growth/environmental conditions) as the context c.  If, in this setting, we 
observe a change in molecule B under inhibition of molecule A, we can conclude 
that there exists a causal pathway (i.e. a sequence of mechanistic events, possibly 
involving additional molecular species) between A and B in context c. 
Conceptually, performing all possible inhibition experiments on a set of 
molecules (including in combinations) would allow construction of a directed 
network Gc, with nodes corresponding to the molecules, and edges encoding 
causal relationships between nodes. Specifically, an edge in Gc indicates that in 
context c, inhibition of the parent node can lead to a change in the child node that 
is not mediated via any other node in the network. We refer to Gc as the context-
specific causal network and to edges therein as causal edges (Figure 1A).  
 
Due to the large number of potentially relevant molecular species, it is likely that 
in any specific study there will be variables that are unmeasured but that 
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nonetheless have a causal influence on one or more measured variables. Suppose 
there is no causal pathway between A and B, but the nodes are correlated due to 
co-regulation by an unobserved node C that is not represented in the graph 
(Figure 1B). Then, since inhibition of A would not be capable of changing B, an 
edge from A to B would not be contained in the ground truth network Gc as 
defined above, regardless of the strength of any correlation or statistical 
dependence between A and B (Figure 1C). A contrasting case is that of a missing 
variable that is intermediate in a causal pathway, e.g. if A influences B via an 
unmeasured molecule C. Then, using the definition above, we would consider the 
edge A->B to be a correct representation of the causal influence. However, if C 
were observed, the correct model would be A->C->B (Figure 1C). Thus, the 
definition we use is compatible with missing variables whilst correctly encoding 
the effect of interventions on observed nodes, but the edges are not intended to 
encode physically direct influences only. We note that there are many subtle and 
still open aspects of the epistemology of interventions and causation; for a wider 
discussion see Woodward (2013). 
 
The definition of causal molecular networks above is rooted in changes under 
inhibition but is not restricted to any particular mechanism. We focus on kinase 
inhibitors, phosphoprotein nodes and relatively short-term changes (up to four 
hours after inhibition) and to that extent our focus is on signaling, but we note 
that changes seen in our data could be due to a number of mechanisms, including 
transcription, translation or protein stability. In considering causal influences, it 
is important to specify a relevant timeframe, because under the same 
intervention, different changes may occur over different time periods (see also 
Discussion). Note also that even if one assumes a very large sample size and 
neglects statistical issues entirely, a notion of magnitude (of change under 
inhibition) remains implicit in the network definition itself and influences the 
sparsity of the ground truth network.  
 




We sought to investigate causal signaling networks in specific biological 
contexts. We considered four breast cancer cell lines (MCF7, UACC812, BT20 and 
BT549) derived from distinct epigenetic states and harboring different genomic 
aberrations (these cell lines have been extensively characterized; see Barretina 
et al., 2012; Garnett et al., 2012; Heiser et al., 2012; Neve et al., 2006). Each cell 
line was serum starved for 24 hours and then at time t=0min stimulated with 
one of eight different stimuli (Figure 2A). For each (cell line, stimulus) context, we 
carried out RPPA time-course assays comprising a total of seven time points 
spanning four hours, and under five different kinase inhibitors plus DMSO as a 
control (Figure 2A and STAR Methods; the assays included additional, later time 
points that were not used in our analyses, but are available in Data S1).  To 
ensure that targets of the kinase inhibitors were effectively blocked, cells were 
treated with inhibitors for two hours before stimulus. Low concentrations of 
each inhibitor were used to minimize off-target effects (see STAR Methods). Due 
to the functional significance of phosphorylation, the analyses presented below 
focus on the 35 phosphoproteins that were measured in all cell lines (see STAR 
Methods and Table S1; Data S1 contains measurements for all antibodies). 
Context-specific changes under intervention were summarized as causal 
descendancy matrices (Figure 2B; see below). Machine learning methods were 
used to integrate the interventional data with known biology to reconstruct 
context-specific signaling networks (Figure 2C).  
  
Interventional time-course data specific to biological context 
Comparing time-course data between inhibitor and control (DMSO) experiments 
allowed us to detect changes to phosphoprotein nodes caused by kinase 
inhibition (see STAR Methods for details). These changes are visualized in a 
global manner for cell line MCF7 in Figure 3B, with DMSO time courses shown in 
Figure 3A. In Figure 3B, the color coding indicates direction of effect (see 
examples in Figure 3C): green indicates a decrease under inhibition relative to 
control (consistent with positive regulation) and red an increase under 
inhibition (consistent with negative regulation). Corresponding visualizations for 




Many effects, including many classical ones, are not stimulus-dependent. For 
example, phospho-p70S6K is reduced relative to control under mTOR inhibition 
(inhibitor AZD8055; Figure 3C), in line with the known causal role of mTOR in 
regulating phosphorylation of p70S6K. Since mTOR signaling is already active in 
serum starved cells, the reduction in phospho-p70S6K under mTOR inhibition is 
seen at all time points, including t=0min (recall that the inhibitor is applied prior 
to stimulus). However, some changes under intervention are specific to 
individual stimuli. Some of these effects can be readily explained, such as the 
reduction in abundance of several phosphoproteins in the AKT and MAPK 
pathways under FGFR inhibition (inhibitor PD173074) for cell line MCF7 
stimulated with FGF1. Other stimulus-specific changes are less expected, 
including the decrease in abundance of phospho-AKT (phosphorylated at 
threonine 308) in cell line MCF7 under inhibition of mTOR/PI3K  (inhibitor 
BEZ235) that is observed in only four of the stimuli.  
 
Causal descendancy matrices summarize changes under intervention 
across multiple contexts 
Changes seen under inhibition of mTOR (catalytic inhibitor AZD8055) are 
summarized in Figure 4A (with phosphoproteins in rows and the 32 contexts in 
columns). Here, a filled-in box for phosphoprotein p in context c indicates a 
salient change under mTOR inhibition (see STAR Methods), consistent with a 
causal influence of mTOR on phosphoprotein p in context c. This could occur via 
a causal pathway involving other (measured or unmeasured) nodes. In other 
words, an entry in location (p,c) in the matrix indicates that phosphoprotein p is 
a descendant of mTOR in the causal network Gc for context c; we therefore refer 
to this matrix as a causal descendancy matrix for mTOR. For comparison, an 
additional column shows proteins that are descendants of mTOR according to a 
canonical signaling network (Figure 4B; STAR Methods). Many classical signaling 
links are conserved across cell lines and stimuli. But there are also many 
examples of influences that are both non-canonical and context-specific; for 
example, phospho-p38 is elevated in UACC812 cells treated with the mTOR 
inhibitor AZD8055 under serum stimulation whereas there is no change in 
BT549 cells under the same conditions. Similarly, we obtained causal 
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descendancy matrices for each of the other inhibitors in our study (Figure S3). 
On average across all kinase inhibitors and pairs of contexts, 8 out of 35 
phosphoproteins show salient changes under inhibition in one context that are 
not seen in the other (mean number of differences = 8.14). Considering only 
pairs of cell lines under the same stimulus the mean number of differences is 
8.58, while considering pairs of stimuli for the same cell line the corresponding 
value is 6.38. This suggests that the differences in (epi)genetic background 
between the cell lines have a relatively pronounced effect. 
 
We sought to validate some of the observed causal effects by western blot 
analysis (STAR Methods). Observations were selected for validation across both 
inhibitors and antibodies, and included instances of increase and decrease under 
inhibition, as well as instances where no effect was observed (Table S2). A 
summary of the number of observations tested for each cell line and inhibitor 
regime, and of validation success rate in independent experiments (i.e. new 
lysates) is shown in Figure 4C.   Overall we validated 78% of observations tested 
(104 out of 134 observations). There were 25 (antibody, inhibitor) combinations 
that for the same stimulus showed differing effects across cell lines in the RPPA 
data (and which were also tested by western blotting); 17 of these instances of 
heterogeneity across cell lines validated (68%). The corresponding validation 
rate for (antibody, inhibitor) combinations that for the same cell line showed 
differing effects across stimuli was only 3 out of 13 (23%). Failures to validate 
could represent biological variability, differential sensitivity between RPPA and 
western blotting, use of different antibodies or other technical issues.  
 
Machine learning of signaling networks 
We used dynamic Bayesian networks to learn context-specific causal networks 
over all measured phosphoprotein nodes (including those not intervened upon). 
To do so, we exploited several recent methodological advances that allow 
integration of interventional data and simultaneous network learning across 
multiple related problem instances (here, contexts; see STAR Methods and 
references therein for details). Known biology was incorporated using a prior 




Figure 5 summarizes networks across all contexts by averaging across the eight 
stimulus-specific networks for each of the four cell lines. We see that while many 
edges, including several classical ones, are near universal, others are cell line-
specific, mirroring, via a global analysis, the inhibition data reported above 
(Figure 4A). The networks contained edges included in the prior network as well 
as many edges that were not. Across the 32 contexts, networks contained an 
average of 49 edges (at a threshold of 0.2 applied to the edge probabilities that 
are the output of the learning procedure) and, on average, 40% of edges in each 
network were not in the prior network (Table S3). We discuss potentially novel 
edges that were not in the prior below.  As discussed in Hill et al. (2016), the 
challenging nature of causal network learning means that empirical performance 
assessment is important. We used an extended variant of the train-and-test 
procedure described in Hill et al. (2016) to systematically assess causal network 
learning (see STAR Methods). We found that the models were able to achieve 
significant agreement with unseen test interventional data in most of the 
contexts (Figure S5). However, we note that empirical assessment is a frontier 
topic in causal inference and the assessment procedure used here is subject to a 
number of caveats (see Discussion).  
  
Validation of context-specific signaling hypotheses 
We identified 235 edges in the inferred networks that were not in the prior 
network. These potentially novel edges shared 35 parent proteins, 4 of which 
were inhibited in the original dataset.  Five edges with parent nodes not among 
those inhibited in the original RPPA data were selected for validation by western 
blot.  Edge selection was done on the basis of biological interest and availability 
of sufficiently specific inhibitors for the parent nodes (Figure 6).  We note that 
our computational approach predicts presence/absence of each (directed) edge, 
but not sign (activating or inhibiting). 
 
For each of the five edges, we tested contexts in which the edge was predicted as 
well as those in which the edge was not predicted.  We inhibited the parent node 
and observed whether this altered abundance of the predicted child node. We 
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found evidence supporting each of the five predicted causal edges, but with often 
complex context-dependence.  These results – and their agreement and 
disagreement with context-specific predictions from network modeling – are 
summarized in Figure 6F,G.       
 
An edge from Chk2_pT68 to p38_pT180/Y182 (for phosphoproteins we give the 
protein name before an underscore which is followed by the phosphorylation 
site(s)) was predicted only in cell line BT549 (Figure 5).  We inhibited Chk2 with 
AZD7762 in BT549 cells, and saw decreases in phospho-p38 under serum (FBS) 
and NRG1, where the edge was predicted, as well as under insulin, where the 
edge was not predicted (Figure 6A).  In contrast, there is no change in phospho-
p38 in BT20 cells under AZD7762 treatment, consistent with the absence of the 
edge in the BT20 networks.  Here we see that the edge validates in a cell line-
specific but not stimulus-specific manner.  However, it is important to note that 
AZD7762 inhibits Chk1 and Chk2 with equal potency and also demonstrates 
activity, albeit lower, against other kinases.  
 
The networks predicted an edge from p38_pT180/Y182 to JNK_pT183/T185 in 
BT549 and BT20 cells under stimulus with FBS.  We inhibited p38 with VX702 in 
BT549, BT20 and UACC812 cells stimulated with FBS. In line with network 
predictions, we observed an increase in phospho-JNK in BT549 and BT20 cells 
(Figure 6B), but also observed a modest increase in phospho-JNK in UACC812 
cells, where the edge was not predicted.   
 
An edge from Src_p416 to NFκβ-p65_pS536 was predicted only in BT20 cells 
stimulated with EGF.  Upon inhibition of Src with KX2391 both before and after 
stimulation with EGF, an increase in the abundance of phospho-NFκβ was 
observed in BT20 cells, consistent with the presence of a causal link (Figure 6C).  
The connection between phospho-Src and phospho-NFκβ was also observed in 
MCF7, where the edge was not predicted.  
 
An edge from p70S6K_pT389 to p27_pT198 was predicted in all of the UACC812 
and BT549 networks.  The edge was also predicted in MCF7 networks for PBS, 
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insulin, FGF, NRG1, and IGF1 and in the BT20 NRG1 network.  When p70S6K was 
inhibited in UACC812 cells with PF4708671, a change in phospho-p27 was 
observed only at the zero time point before stimulus was added (Figure 6D).  In 
MCF7 cells stimulated with HGF, phospho-p27 decreased in abundance under 
p70S6K inhibition; however, the edge was not predicted in this context.  When 
PF4708671-treated MCF7 cells were stimulated with IGF, a context in which the 
edge was predicted with high probability, no change in phospho-p27 was 
observed.  Similarly, there was no change in phospho-p27 in BT20 cells that had 
been treated with PF4708671 and stimulated with HGF.  
 
In BT549 an edge was predicted from Chk2_pT68 to YAP_pS127 under HGF and 
insulin.  BT549 cells treated with the Chk2 inhibitor AZD7762 exhibit an increase 
in phospho-YAP (Figure 6E).  This edge was not predicted in any other cell line 
tested.  However, in both UACC812 and MCF7 cells treated with AZD7762, a 
decrease in the abundance of phospho-YAP is observed.  Active Chk2 appears to 
decrease phospho-YAP in BT549 cells (where the edge was predicted) and 
increase phospho-YAP in UACC812 and MCF7 cells (where the edge was not 
predicted).  These results are consistent with the existence of a causal influence 
of phospho-Chk2 on phospho-YAP in all of these cell lines, and not just in BT549 
as predicted.  
 
Discussion  
The data and analyses presented here support the notion that causal molecular 
networks can depend on context. We focused on signaling proteins and breast 
cancer cell lines. The cell lines represent contexts that are genetically perturbed 
but with a shared cancer type. The heterogeneity that we observed in causal 
networks suggests that substantial differences could exist between, for example, 
samples from different tissue types or divergent environmental conditions. This 
strongly argues for a need to refine existing regulatory models for specific 
contexts, not least in disease biology. 
 
Given the range of potentially relevant contexts – spanning combinations of 
multiple factors, including genetic, epigenetic and environmental – we do not 
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believe that characterization of causal networks across multiple contexts can 
feasibly be done using classical approaches in a protein-by-protein manner. 
Rather, it will require high-throughput data acquisition and computational 
analysis. Such a program of research requires an appropriate conceptual 
framework, rich enough to capture regulatory relationships, but still tractable 
enough for large-scale investigation. Furthermore, for practical application, such 
an approach needs to be sufficiently robust to missing or unknown variables. 
Causal models of the kind we discussed may provide an appropriate framework 
because, unlike purely correlational models, they allow for reasoning about 
change under intervention and are, to a certain extent, robust to missing 
variables. In particular, causal descendancy matrices (Figures 4A and S3) are 
robust to missing variables in the sense that addition of a protein (row) to the 
matrix would not change the existing entries. We expect that a systematic 
program of investigation into context-specific causal networks will be important 
in many disease areas, and perhaps especially those that have to date not been 
well represented in the literature. 
 
Our results extend the well-established notion of genomic intertumoral 
heterogeneity in cancer to the level of signaling phenotype. We found that cell 
line-specific findings were more reliable than stimulus-specific findings. This 
may be due to the magnitude of epigenetic and genetic differences between cell 
lines being more marked than differences between stimuli, all of which activate 
closely related cell surface receptors.  
 
Our approach relied on inhibitor specificity, but we note that even at relatively 
low concentrations, off-target effects cannot be entirely ruled out. However, if 
the inhibitors were highly non-specific, the relatively good results seen in the 
train-and-test analysis would likely not be possible, since the analysis relies on 
assumed inhibitor targets. In the future it may be relevant to consider models 
that allow uncertainty in the inhibitor targets themselves.  
 
We highlighted the need to specify a relevant timeframe in defining a causal 
graph. Indeed, an inhibitor may in the short-to-medium term induce changes to 
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specific molecules but over the longer term the same inhibitor might induce 
adaptive changes to the cells themselves, e.g. via changes to epigenetic state 
(Duncan et al., 2012; Lee et al., 2012). We did not consider such “rewiring” in this 
paper, but note that the methods we discussed could be used to study rewiring, 
e.g. by comparing networks before and after adaptation.  
 
 
In common with most protein profiling studies, including both low- and high-
throughput techniques, our experiments were based on bulk assays and can 
therefore only elucidate signaling heterogeneity at the level of cell populations; 
we did not consider cell-to-cell heterogeneity, tumor stromal interactions, nor 
the spatial heterogeneity of tumors that plays an important role in vivo (Bedard 
et al., 2013; González-García et al., 2002). However, our data have implications 
for inter- and intra-tumoral heterogeneity because they suggest the possibility 
that in vivo causal signaling networks – and in turn the cell fates and disease 
progression events that they influence – may depend on the local micro-
environment. Further work will be needed to elucidate such dependence and to 
draw out its implications.  
 
In the future, causal molecular networks may start to play a role in precision 
medicine, for example by helping to inform rational assignment of targeted 
therapies. An implication of the context-specificity we report is that such 
analyses may require models that are learned, or at least modified, for individual 
samples (or subsets of samples). Although causal models are in some ways 
simpler than fully dynamical ones, causal inference remains fundamentally 
challenging and is very much an open area of research. For this reason, alongside 
advances in relevant assays, a personalized, network-based approach will 
require suitable empirical diagnostics. Hill et al. (2016) used the data presented 
here to score, in an automated manner, over 2000 networks (~70 methods each 
applied to infer 32 context-specific networks) submitted to the HPN-DREAM 
network inference challenge and we used an extended version of this assessment 
procedure here. Such assessment procedures might allow for automated quality 
control, for example rejecting networks not sufficiently consistent with unseen 
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interventional readouts (e.g. we did not obtain statistically significant 
performance under any test inhibitor for the (BT549, EGF) context; see Figure 
S5). However, as discussed in Hill et al. (2016) the assessment procedure 
remains limited in several ways and this argues for caution in interpreting the 
relatively good performance reported here. Of particular relevance to context-
specificity, we note that the procedure focuses on global agreement with held-
out interventional data and not specifically on identification of differences 
between contexts. Indeed, our validation experiments showed that although all 
novel edges that were tested validated in one or more contexts, network 
predictions were not accurate with respect to the precise context(s) in which 
changes were seen.  
 
Recently, Carvunis and Ideker (2014) proposed a view of cellular function 
involving hierarchies of elements and processes and not just networks. Building 
detailed dynamical or biophysical models over hierarchies spanning multiple 
time and spatial scales may prove infeasible. A more tractable approach may be 
to extend coarser causal models of the kind used here in a hierarchical direction, 
for example by allowing causal links to cross scales and subsystems. Thus, the 
approach we pursued – of causal models based on context-specific interventional 
data – could in the future be used to populate models over biological hierarchies. 
 
Author Contributions 
S.M.H. carried out analyses. N.K.N., K.J.-C., M.J., A.J., C.B., Y.L., and N.T.P. carried 
out the cell culture and inhibition experiments. S.E.F.S. contributed to analyses. 
Y.L. generated the RPPA data under the supervision of G.B.M. L.M.H. provided 
technical analyses. J.E.K. and J.W.G. provided experimental design. S.M.H., S.M. & 
P.T.S. designed analyses. G.B.M., S.M. & P.T.S. conceived and led the study. S.M.H., 
N.K.N., G.B.M., S.M. & P.T.S. wrote the paper. 
 
Acknowledgments 
This work was supported by the National Institutes of Health National Cancer 
Institute (grant U54 CA112970 to J.W.G., G.B.M., S.M. and P.T.S.). S.M.H. and S.M. 
were supported by the UK Medical Research Council (Unit Programme numbers 
 16 
 
MC_UP_1302/1 and MC_UP_1302/3). S.M. was a recipient of a Royal Society 
Wolfson Research Merit Award. The MD Anderson Cancer Center RPPA Core 
Facility is funded by the National Institutes of Health National Cancer Institute 
(Cancer Center Core Grant CA16672). 
 
References 
Akbani, R., Ng, P.K.S., Werner, H.M.J., Shahmoradgoli, M., Zhang, F., Ju, Z., Liu, W., 
Yang, J.-Y., Yoshihara, K., Li, J., et al. (2014). A pan-cancer proteomic perspective 
on The Cancer Genome Atlas. Nat. Commun. 5, 3887. 
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., 
Wilson, C.J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012). The Cancer Cell Line 
Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 
483, 603–307. 
Bedard, P.L., Hansen, A.R., Ratain, M.J., and Siu, L.L. (2013). Tumour 
heterogeneity in the clinic. Nature 501, 355–364. 
Benjamini, Y., Krieger, A.M., and Yekutieli, D. (2006). Adaptive linear step-up 
procedures that control the false discovery rate. Biometrika 93, 491–507. 
Cantone, I., Marucci, L., Iorio, F., Ricci, M.A., Belcastro, V., Bansal, M., Santini, S., di 
Bernardo, M., di Bernardo, D., and Cosma, M.P. (2009). A yeast synthetic network 
for in vivo assessment of reverse-engineering and modeling approaches. Cell 
137, 172–181. 
Carvunis, A.-R., and Ideker, T. (2014). Siri of the cell: what biology could learn 
from the iPhone. Cell 157, 534–538. 
Coombes, K.R., Neeley, S., Joy, C., Hu, J., Baggerly, K., and Roebuck, P. (2012). 
SuperCurve: SuperCurve R Package. 
Duncan, J.S., Whittle, M.C., Nakamura, K., Abell, A.N., Midland, A.A., Zawistowski, 
J.S., Johnson, N.L., Granger, D.A., Jordan, N.V., Darr, D.B., et al. (2012). Dynamic 
Reprogramming of the Kinome in Response to Targeted MEK Inhibition in 
Triple-Negative Breast Cancer. Cell 149, 307–321. 
Garnett, M.J., Edelman, E.J., Heidorn, S.J., Greenman, C.D., Dastur, A., Lau, K.W., 
Greninger, P., Thompson, I.R., Luo, X., Soares, J., et al. (2012). Systematic 
identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 
570–575. 
Gerlinger, M., and Swanton, C. (2010). How Darwinian models inform 
therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. 
Cancer 103, 1139–1143. 
 17 
 
González-García, I., Solé, R. V, and Costa, J. (2002). Metapopulation dynamics and 
spatial heterogeneity in cancer. Proc. Natl. Acad. Sci. U. S. A. 99, 13085–13089. 
Good, M., Tang, G., Singleton, J., Reményi, A., and Lim, W.A. (2009). The Ste5 
scaffold directs mating signaling by catalytically unlocking the Fus3 MAP kinase 
for activation. Cell 136, 1085–1097. 
Heiser, L.M., Sadanandam, A., Kuo, W., Benz, S.C., Goldstein, T.C., Ng, S., Gibb, W.J., 
Wang, N.J., Ziyad, S., Tong, F., et al. (2012). Subtype and pathway specific 
responses to anticancer compounds in breast cancer. Proc. Natl. Acad. Sci. U. S. A. 
109, 2724–2729. 
Hennessy, B.T., Lu, Y., Gonzalez-Angulo, A.M., Carey, M.S., Myhre, S., Ju, Z., Davies, 
M.A., Liu, W., Coombes, K., Meric-Bernstam, F., et al. (2010). A Technical 
Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the 
Functional Proteome in Non-microdissected Human Breast Cancers. Clin. 
Proteomics 6, 129–151. 
Hill, S.M., Lu, Y., Molina, J., Heiser, L.M., Spellman, P.T., Speed, T.P., Gray, J.W., 
Mills, G.B., and Mukherjee, S. (2012). Bayesian inference of signaling network 
topology in a cancer cell line. Bioinformatics 28, 2804–2810. 
Hill, S.M., Heiser, L.M., Cokelaer, T., Unger, M., Nesser, N.K., Carlin, D.E., Zhang, Y., 
Sokolov, A., Paull, E.O., Wong, C.K., et al. (2016). Inferring causal molecular 
networks: empirical assessment through a community-based effort. Nat. 
Methods 13, 310–318. 
Hu, J., He, X., Baggerly, K. a., Coombes, K.R., Hennessy, B.T.J., and Mills, G.B. 
(2007). Non-parametric quantification of protein lysate arrays. Bioinformatics 
23, 1986–1994. 
Hu, Y., Yan, C., Hsu, C., Chen, Q., Niu, K., and Komatsoulis, G. a (2014). A 
Comprehensive Comparison of Normalization Methods for Loading Control and 
Variance Stabilization of Reverse-Phase Protein Array Data. Cancer Inform. 13, 
109–117. 
Husmeier, D. (2003). Sensitivity and specificity of inferring genetic regulatory 
interactions from microarray experiments with dynamic Bayesian networks. 
Bioinformatics 19, 2271–2282. 
Lee, M.J., Ye, A.S., Gardino, A.K., Heijink, A.M., Sorger, P.K., MacBeath, G., and Yaffe, 
M.B. (2012). Sequential Application of Anticancer Drugs Enhances Cell Death by 
Rewiring Apoptotic Signaling Networks. Cell 149, 780–794. 
Li, J., Lu, Y., Akbani, R., Ju, Z., Roebuck, P.L., Liu, W., Yang, J.-Y., Broom, B.M., 
Verhaak, R.G.W., Kane, D.W., et al. (2013). TCPA: a resource for cancer functional 
proteomics data. Nat. Methods 10, 1046–1047. 
 18 
 
Marbach, D., Prill, R.J., Schaffter, T., Mattiussi, C., Floreano, D., and Stolovitzky, G. 
(2010). Revealing strengths and weaknesses of methods for gene network 
inference. Proc. Natl. Acad. Sci. U. S. A. 107, 6286–6291. 
Marbach, D., Lamparter, D., Quon, G., Kellis, M., Kutalik, Z., and Bergmann, S. 
(2016). Tissue-specific regulatory circuits reveal variable modular perturbations 
across complex diseases. Nat. Methods 13, 366–370. 
Murphy, K. (2002). Dynamic Bayesian Networks: Representation, Inference and 
Learning. University of California, Berkeley, CA. 
Neve, R.M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F.L., Fevr, T., Clark, L., Bayani, 
N., Coppe, J.-P., Tong, F., et al. (2006). A collection of breast cancer cell lines for 
the study of functionally distinct cancer subtypes. Cancer Cell 10, 515–527. 
Nickel, G.C., Barnholtz-Sloan, J., Gould, M.P., McMahon, S., Cohen, A., Adams, M.D., 
Guda, K., Cohen, M., Sloan, A.E., and LaFramboise, T. (2012). Characterizing 
mutational heterogeneity in a glioblastoma patient with double recurrence. PLoS 
One 7, e35262. 
Oates, C.J., Korkola, J., Gray, J.W., and Mukherjee, S. (2014). Joint estimation of 
multiple related biological networks. Ann. Appl. Stat. 8, 1892–1919. 
Pearl, J. (2009). Causality: Models, Reasoning, and Inference (Cambridge 
University Press). 
Petsalaki, E., Helbig, A.O., Gopal, A., Pasculescu, A., Roth, F.P., and Pawson, T. 
(2015). SELPHI: correlation-based identification of kinase-associated networks 
from global phospho-proteomics data sets. Nucleic Acids Res. 43, W276–W282. 
Rolland, T., Ta An, M., Charloteaux, B., Pevzner, S.J., Zhong, Q., Sahni, N., Yi, S., 
Lemmens, I., Fontanillo, C., Mosca, R., et al. (2014). A Proteome-Scale Map of the 
Human Interactome Network. Cell 159, 1212–1226. 
Saez-Rodriguez, J., Goldsipe, A., Muhlich, J., Alexopoulos, L.G., Millard, B., 
Lauffenburger, D. a., and Sorger, P.K. (2008). Flexible informatics for linking 
experimental data to mathematical models via DataRail. Bioinformatics 24, 840–
847. 
Saez-Rodriguez, J., Alexopoulos, L.G., Zhang, M., Morris, M.K., Lauffenburger, D. a, 
and Sorger, P.K. (2011). Comparing signaling networks between normal and 
transformed hepatocytes using discrete logical models. Cancer Res. 71, 5400–
5411. 
Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., 
Schwikowski, B., and Ideker, T. (2003). Cytoscape: a software environment for 




De Smet, R., and Marchal, K. (2010). Advantages and limitations of current 
network inference methods. Nat. Rev. Microbiol. 8, 717–729. 
Spencer, S.E.F., Hill, S.M., and Mukherjee, S. (2015). Inferring network structure 
from interventional time-course experiments. Ann. Appl. Stat. 9, 507–524. 
Spirtes, P., Glymour, C.N., and Scheines, R. (2000). Causation, Prediction, and 
Search (MIT Press). 
Szerlip, N.J., Pedraza, A., Chakravarty, D., Azim, M., McGuire, J., Fang, Y., Ozawa, T., 
Holland, E.C., Huse, J.T., Jhanwar, S., et al. (2012). Intratumoral heterogeneity of 
receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma 
defines subpopulations with distinct growth factor response. Proc. Natl. Acad. 
Sci. U. S. A. 109, 3041–3046. 
Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G.B., and Kornblau, S.M. 
(2006). Reverse phase protein array: validation of a novel proteomic technology 
and utility for analysis of primary leukemia specimens and hematopoietic stem 
cells. Mol. Cancer Ther. 5, 2512–2521. 
Weinberg, R. (2013). The Biology of Cancer (Garland Science). 
Will, T., and Helms, V. (2016). PPIXpress: construction of condition-specific 
protein interaction networks based on transcript expression. Bioinformatics 32, 
571–578. 
Woodward, J. (2013). Causation and Manipulability. In The Stanford 
Encyclopedia of Philosophy, E.N. Zalta, ed. 
Zalatan, J.G., Coyle, S.M., Rajan, S., Sidhu, S.S., and Lim, W.A. (2012). 
Conformational control of the Ste5 scaffold protein insulates against MAP kinase 




Figure 1. Context-specific Causal Networks.  
(A) Context-specific causal influences. Node A has a causal influence on node B in 
contexts c1 and c3, but not c2, encoded by the presence of a causal edge between A 
and B in c1 and c3 only. This reflects the outcome of experiments where A is 
inhibited. Here, each context is defined by the combination of cell line and 
growth condition. (B) Correlation and causation. The abundance of node A is 
correlated with that of node B due to regulation by the same node C. However, as 
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there is no causal influence (direct or indirect) of A on B, inhibition of A does not 
result in a change in the abundance of B, no matter how strong the correlation or 
statistical dependence. (C) Causal networks and missing nodes. In the first 
example, node C regulates both nodes A and B (as in panel (B)). In the 
formulation used here, if C is not observed and not included in the network, but A 
and B are, we would regard the network with no edge between A and B in either 
direction as the correct or ground truth causal network, in line with the results of 
experimental inhibition of these nodes, as shown. In the second example, the 
underlying mechanism is that A influences C, and C in turn influences B. In the 
formulation used here, if C is not measured and not included in the network, an 
edge from A to B would be regarded as correct, in line with the results of 
experimental inhibition of the nodes.  However, if all three nodes were included, 
the correct network would match the underlying mechanism. Although 
abundance of B changes under inhibition of A, an edge from A to B would be 
regarded as incorrect here because the influence of A on B is fully mediated via 
another network node (i.e. C). See text for further details of the causal 
formulation and its interpretation.  
 
Figure 2. Data-Driven Reconstruction of Context-Specific Causal Signaling 
Networks. 
(A) Overview of experimental approach. Reverse-phase protein arrays (RPPA) 
were used to investigate protein signaling in four human breast cancer cell lines 
under eight different stimuli. The combinations of cell line and stimulus defined 
32 (cell line, stimulus) contexts. Prior to stimulus, cell lines were serum starved 
and treated with kinase inhibitors or DMSO control. RPPA assays were 
performed for each context at multiple time points post-stimulus, using more 
than 150 high-quality antibodies to target specific proteins, including 
approximately 40 phosphoproteins (the precise number of antibodies varies 
across cell lines; see STAR Methods and Table S1). (B) Causal descendancy 
matrices (CDMs). CDMs summarizing changes under intervention across all 
contexts were constructed for each intervention (see text for details). (C) 
Overview of causal network learning procedure. Interventional time-course data 
for each context were combined with existing biological knowledge in the form 
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of a prior network to learn context-specific phosphoprotein signaling networks. 
Networks were learned using a variant of dynamic Bayesian networks designed 
for use with interventional data and that allowed joint learning over all 32 
contexts at once (see STAR Methods). 
 
Figure 3. Phosphoprotein Time-Course Data and Context-Specific Changes 
Under Inhibition for Breast Cancer Cell Line MCF7. 
(A) Phosphoprotein time courses under DMSO control. Rows correspond to 35 
phosphoproteins (a subset of the full set of 48; see STAR Methods for details) 
and columns correspond to the eight stimuli. Each time course shows log2 ratios 
of phosphoprotein abundance relative to abundance at t = 0. Shading represents 
average log2 ratio for t > 0. (B) Phosphoprotein time courses under kinase 
inhibition. Each of the five vertical blocks corresponds to a different inhibition 
regime. Within each block, rows and columns are as in (A). Each time course 
shows log2 ratios of phosphoprotein abundance under inhibition relative to 
abundance under DMSO control. Shading represents direction of changes in 
abundance due to inhibitor: Green denotes a decrease in abundance, red denotes 
an increase and gray denotes no salient change (see examples in panel (C)). See 
STAR Methods for details of statistical analysis. For both (A) and (B), plots were 
generated using a modified version of the DataRail software (Saez-Rodriguez et 
al., 2008). Each phosphoprotein is plotted on its own scale and phosphoproteins 
are ordered by hierarchical clustering of all data. See Figure S1 for 
corresponding plots for cell lines UACC812, BT20 and BT549. (C) Selected 
examples from (B) showing control (DMSO) and inhibitor time courses 
separately; box color identifies the source cell in (B). Examples are shown for 
(from left to right): a clear decrease in abundance ; a clear increase in 
abundance; a decrease in abundance that is borderline under the criteria we use; 
a borderline case called negative (i.e. called as no change) and a clear negative 
case. Shaded region indicates time-averaged replicate standard deviation. See 
also Figure S2. 
 
Figure 4. Non-Canonical and Context-Specific Signaling. 
(A) Causal descendancy matrix showing causal effects observed under mTOR 
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inhibitor AZD8055 in each of the 32 (cell line, stimulus) contexts. Rows represent 
phosphoproteins and columns represent contexts (see Figure 3). Black boxes 
indicate phosphoproteins that show a salient change under mTOR inhibition in a 
given context (see STAR Methods) and can therefore be regarded as causal 
descendants of mTOR in the signaling network for that context. The final column 
on the right indicates phosphoproteins that are descendants of mTOR in the 
canonical mTOR signaling pathway shown in (B). Phosphoproteins are ordered 
first by canonical column and then by hierarchical clustering of all data. See 
Figure S3 for causal descendancy matrices for the other inhibitor regimes. (B) 
Canonical mTOR signaling pathway. Blue nodes are descendants of mTOR in the 
network and white nodes are non-descendants. The pathway shown is a 
subnetwork of the prior network used within the network inference procedure 
(Figure S4). Full node names, including phosphorylation sites, are provided in 
Table S4. (C) Summary of western blot validations of causal effects observed in 
RPPA data.  A number of observations from the causal descendancy matrices 
were chosen for validation via western blot analysis.  The number of 
phosphoprotein validations attempted (“Tested”) and the number of these that 
successfully validated (“Validated”) are presented for various (cell line, stimulus, 
inhibitor) combinations.  Summary totals are also presented for each cell line, 
each inhibitor and across all validation experiments. See also Table S2. 
 
Figure 5. Context-Specific Signaling Networks Reconstructed Using a 
Machine Learning Approach. 
Data for 35 phosphoproteins were analyzed using a machine learning approach 
based on interventional dynamic Bayesian networks, integrating also known 
biology in the form of a prior network (Figure S4). This gave a set of scores (edge 
probabilities) for each possible edge in each (cell line, stimulus) context (see 
STAR Methods). For each cell line, a summary network was obtained by 
averaging edge probability scores across the eight stimulus-specific networks for 
that cell line. Edge color denotes cell line. Only edges with average probabilities 
greater than 0.2 are shown. A black edge indicates an edge that appears (i.e. is 
above the 0.2 threshold) in all four cell lines. Edge thickness is proportional to 
the average edge probability (average taken across all 32 contexts for black 
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edges). Solid/dashed edges were present/not present in the prior network 
respectively. Edges are directed with the child node indicated by a circle. Edge 
signs are not reported; the modeling approach does not distinguish between 
excitatory and inhibitory causal effects. Full nodes names, including 
phosphorylation sites, are provided in Table S4. Network visualized using 
Cytoscape (Shannon et al., 2003). See also Table S3. 
 
Figure 6. Validation of Network Edges. 
Western blot analysis of selected context-specific network edges that were not in 
the prior network. Edges tested were: (A) phospho-Chk2 to phospho-p38 ; (B) 
phospho-p38 to phospho-JNK; (C) phospho-Src to phospho-NFκB; (D) phospho-
p70S6K to phospho-p27; and (E) phospho-Chk2 to phospho-YAP. Orange boxed 
areas indicate observed changes in abundance of the predicted child node under 
inhibition of the parent node in a single (cell line, stimulus) context (changes in 
abundance are determined by visual inspection of the bands). Edge probabilities 
output by the network learning procedure are shown for each context tested 
(“edge strength”). (F) A summary of the validation experiments.  ‘NA’ denotes 
“not applicable” – the experiment was not run.  ‘NE’ denotes “no effect” – there 
was no change in child node abundance upon inhibition of the parent node.  An 
arrow indicates results consistent with an activating parent node.  A stunted line 
represents results consistent with an inhibitory edge.  Symbols are colored 
orange to indicate that an edge was predicted for the corresponding cell line 
under one of the stimuli tested. (G) Summary of agreement and disagreement 
between predicted edges and validation experiments. First row indicates 
whether validation experiments showed evidence for the edge in a (cell line, 
stimulus) context in which it was predicted. Second and third rows concern the 
cell line- and stimulus-specificity of each edge respectively:  a green tick denotes 
specificity in (partial) agreement with predictions from inferred networks; an 
orange tick denotes specificity, but not in agreement with predictions in terms of 
the precise contexts in which effects were seen; a red cross indicates that 
specificity was not observed in the validation experiments, despite being 







KEY RESOURCES TABLE 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for reagents and resources may be directed to, 
and will be fulfilled by, the corresponding author Paul T. Spellman 
(spellmap@ohsu.edu). 
 
EXPERIMENTAL MODEL DETAILS 
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Breast epithelial cells in log-phase of growth were harvested, diluted in the 
appropriate media (DMEM (with phenol red) for UACC812, BT20 and MCF7; 
RPMI (with phenol red) for BT549) containing 10% fetal bovine serum, and then 
seeded into 6 well plates at an optimized cell density (to give 60-75% confluence 
at time of lysis). BT20 cells were plated at 230,000 cells/well; BT549 cells were 
plated at 175,000 cells/well; MCF7 cells were plated at 215,000 cells/well; and 
UACC812 cells were plated at 510,000 cells/well. After 24 hours of growth at 
37°C and 5% CO2 in complete medium, cells were synchronized by incubating 
with serum-free medium for an additional 24 hours (serum starvation was also 
necessary to control the presence of stimuli in the medium). The medium was 
then exchanged with fresh serum-free medium containing either: 15nM 
AZD8055, 50nM GSK690693, 50nM BEZ235, 150nM PD173074, 10nM 
GSK1120212 in combination with 50nM GSK690693, or vehicle alone (0.05% 
DMSO) and incubated for two hours prior to stimulation. Cells were then either 
harvested (0 time point) or stimulated by addition of 200μL per well of 10X 
stimulus (either PBS, fetal bovine serum, 100 ng/mL EGF, 200ng/mL IGF1, 
100nM insulin, 200ng/mL FGF1, 1μg/mL NRG1, or 500 ng/mL HGF) for 0, 5, 15, 
30 or 60 minutes, or 2, 4, 12, 24, 48 or 72 hours prior to protein harvest.  
All cell lines have been authenticated by performing STR analysis and matching 
to reference STR profiles at 15 different loci. STR analysis was performed by 
Genetica Cell Line Testing. 
METHOD DETAILS 
Preparation of Cells for Reverse-Phase Protein Array (RPPA) Analysis 
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Cells were grown as described above, then washed twice with PBS and lysed by 
adding lysis buffer obtained from MD Anderson Functional Proteomics RPPA 
Core Facility (Houston, Texas; lysis buffer comprised 1% Triton X-100, 50mM 
HEPES, pH 7.4, 150mM NaCl, 1.5mM MgCl2, 1mM EGTA, 100mM NaF, 10mM Na 
pyrophosphate, 1mM Na3VO4, 10% glycerol; protease and phosphatase 
inhibitors were freshly added on the day of the experiment). Volume of lysis 
buffer used was optimized for each cell line (to ensure lysates were not too 
dense for the BCA assay; see below) and varied between 50μL and 100μL. 
Lysates were collected by scraping after 20 minutes incubation on ice. Lysates 
were spun at 4°C in a tabletop centrifuge at 15,000 RPM for 10 minutes and 
soluble proteins contained in the supernatant were collected. Protein 
concentration was determined by the Pierce BCA Protein Assay according to 
manufacturer’s protocol. Protein was then diluted to 1 mg/mL and 30μL of the 
diluted lysate was mixed with 10μL 4X SDS sample buffer (obtained from MD 
Anderson Functional Proteomics RPPA Core Facility; comprised 40% Glycerol, 
8% SDS, 0.25M Tris-HCL, pH 6.8; 10% v/v 2-mercaptoethanol was added fresh) 
and boiled for 5 minutes prior to freezing and shipment to MD Anderson Cancer 
Center Functional Proteomics RPPA Core Facility for RPPA analysis (Tibes et al., 
2006).  
RPPA methodology 
RPPA methodology has been described previously (see e.g. Akbani et al., 2014); 
an outline is also provided below. Lysates were diluted in five two-fold serial 
dilutions with lysis buffer. An Aushon Biosystems 2470 arrayer (Burlington, MA) 
was used to print 1056 samples and control lysates on nitrocellulose-coated 
slides (Grace Bio-Labs). Each slide was probed with a primary antibody and a 
biotin-conjugated secondary antibody. Antibodies go through a validation 
process as previously described (Hennessy et al., 2010) to assess specificity, 
quantification and dynamic range. Each of the 183 primary antibodies was 
assigned a label based on this validation process (at the time the assay was 
performed): “validated”, “use with caution” or “under evaluation” (see Table S1). 
Samples were split across three batches and some antibodies were used only in a 
subset of these batches (Table S1). A DakoCytomation-catalyzed system and DAB 
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colorimetric reaction was used to capture signal. Following scanning of slides, 
spot intensities were analyzed and quantified using Microvigene software 
(VigeneTech Inc., Carlisle, MA). The EC50 values of the proteins in each dilution 
series were estimated using the SuperCurve software (Coombes et al., 2012), 
available at http://bioinformatics.mdanderson.org/Software/supercurve/. This 
uses the non-parametric, monotone increasing B-spline model (Hu et al., 2007) 
to fit a single curve (“supercurve”) using all samples on a slide, with signal 
intensity as the response variable and dilution step as the independent variable. 
The fitted curve is plotted with the signal intensities on the y-axis and the log2 
protein concentrations on the x-axis for diagnostic purposes. A quality control 
(QC) metric, between zero and one was calculated for each slide (Coombes et al., 
2012) and slides with values less than 0.8 were excluded. Within each batch, 
measurements were normalized for protein loading by median centering across 
antibodies (Hu et al., 2014; Li et al., 2013). This normalization process, 
performed on log2 concentrations, comprised the following steps: 
1. For each antibody, calculate the median across samples and subtract from 
each value (i.e. median-center each antibody). 
2. For each sample, calculate the median across antibodies to obtain a 
correction factor (CF). 
3. For each sample, take the original log2 concentration values and subtract 
the corresponding CF (from step 2). 
Normalized values, on a linear scale, are provided in Data S1. 
Western Blot Analysis 
Cells were grown as described above. For the novel edge validations in Figure 6, 
additional inhibitors were used to generate lysates following the protocol laid 
out above. The inhibitors, all used at 1μM, were AZD7762, KX2-391, PF4708671, 
and VX-702 (see Figure 6 for targets). Lysates were harvested 15 minutes after 
stimulation and protein concentrations quantified as described above. 
Denatured lysates were separated by PAGE on 4–12% Bis-Tris gradient gels 
(Invitrogen) along with Precision Plus Protein Standards (BioRad) using MOPS 
SDS NuPAGE Running Buffer (Invitrogen) and NuPAGE LDS Sample Buffer 
(Invitrogen) on ice at 200 V for 45 minutes. Gels were transferred to immobilin-
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FL PVDF membranes (Millipore) using NuPAGE Transfer Buffer (Invitrogen) on 
ice at 30 V for 1.5 hours before being washed 3x 5 min. with 5% Tween-TBS 
(TTBS, Amresco & Invitrogen) at room temperature (RT) with agitation  and 
blocked with 5% BSA (Sigma) in TTBS for 1 hour at RT with agitation.  Blots 
were again washed 3x 5 minutes in TTBS at RT with agitation before being 
incubated in primary antibody in 5% BSA in TTBS overnight at 4C with agitation. 
Blots were washed 3x for 5 minutes at RT with agitation and then transferred to 
HRP-conjugated secondary antibody in 5% BSA in TTBS and incubated at RT for 
1.5 hrs. See Table S5 for primary antibodies and HRP-conjugated secondary 
antibodies used in western blot validations. Blots were washed again as 
previously described and visualized using SuperSignal West Pico 
Chemiluminescent HRP Substrate Kit (Thermo Scientific) and CL-X Posure Film 
(Thermo Scientific) and changes in protein abundance under inhibition were 
determined by visual inspection of exposed film. 
 
Quality Control and Preprocessing of RPPA Data 
Batch Normalization Procedure for Cell Line UACC812 
The UACC812 data were split across two RPPA experiments with each batch 
containing different inhibitors (BEZ235, PD173074 and 
GSK690693&GSK1120212 in one batch; AZD8055 and GSK690693 in the other). 
DMSO control samples were common to both batches. The two batches were 
combined and normalized to obtain a single data set for UACC812.  
 
The steps of the batch normalization procedure were as follows: 
1. Any antibodies not included in both batches were removed. 
For each antibody, perform steps 2 and 3 below. 
2. Using log2-transformed data (after normalization for protein loading; see 
above), the mean and standard deviation of the DMSO samples in each 
batch were calculated, giving values (𝜇1,𝜎1) and (𝜇2,𝜎2) for batch 1 and 
batch 2 respectively. Note that, for each batch, there are 16 replicates for 
DMSO, 0min samples (all other DMSO conditions consist of a single 
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replicate). These 16 replicates were averaged prior to calculation of mean 
values and standard deviations.  
3. All samples in batch 2 (for the given antibody) were then scaled and 
centered so that the mean and standard deviation of the batch 2 DMSO 
samples agreed with the corresponding batch 1 quantities (𝜇1, 𝜎1). That 





This scaling and centering was applied to each individual replicate and 
not to replicate-averaged data.  
4. The two batches were then combined to get a single data set for 
UACC812.  
 
Data for the two batches and the final normalized data set are provided in Data 
S1 on a linear scale. 
 
Samples Excluded from Analyses 
Samples identified as outliers were excluded from our analyses. These samples 
were identified using the following criteria: 
 Normalization for protein loading resulted in a correction factor (CF) for 
each sample (see above). Samples with CF > 2.5 or CF < 0.25 were 
regarded as outliers. 
 Variance across all antibodies was calculated for each sample. Values 
greater than 40 were regarded as outliers. 
 We used the replicates at time t = 0 to calculate the signal-to-noise ratio 
(SNR) for each cell line and phosphoprotein antibody under each 
inhibitor (mean of replicates divided by standard deviation of replicates). 
The mean across all calculated SNRs was 10.68 (s.d. = 5.8). SNR values 
less than 1 were investigated further to determine whether the poor SNR 
was caused by outlier replicates. 





In addition to the above, data for the combination of inhibitors GSK690693 & 
GSK1120212 (AKTi & MEKi) for cell lines BT549 (all stimuli) and BT20 (PBS and 
NRG1 stimuli only) were excluded since none of the expected effects of MEKi 
were observed in these samples. 
 
All samples excluded from analyses are shown in Table S6 and also indicated in 
the data files in Data S1. 
 
Antibodies Included in Analyses 
To facilitate comparisons between cell lines, the analyses presented here focused 
on the set of phosphoprotein antibodies common to all four lines. This set 
contained two highly correlated pairs of antibodies (r > 0.9 for all cell lines), 
consisting of phosphoforms of the same protein: GSK3αβ_pS21_pS9, GSK3_pS9 
and S6_pS235_S236, S6_pS240_S244. Since highly correlated variables can lead 
to a reduction in the utility of network inference results, only one antibody out of 
each pair was included in analyses, resulting in a final set of 35 phosphoprotein 
antibodies. A full list of antibodies can be found in Table S1, where the 35 
phosphoproteins included in the analyses are also indicated. 
 
Final Preprocessing Steps 
Data were log2 transformed and replicates (only present for t = 0 samples and 
some DMSO samples) were averaged. Prior to input into our network inference 
pipeline, imputation was performed for missing data by linear interpolation of 
adjacent time points. 
Identification of Changes Under Kinase Inhibition 
We used a procedure centered on paired t-tests to determine which 
phosphoproteins show a salient change in abundance under each kinase 
inhibitor. Details are described in Hill et al. (2016), but also outlined below for 
completeness. 
 
For each phosphoprotein, inhibitor regime and (cell line, stimulus) context, a 
paired t-test was used to assess whether mean phosphoprotein abundance 
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under DMSO control is significantly different to mean abundance under the 
inhibitor regime (mean values calculated over seven time points). As discussed 
above, some phosphoproteins show a clear response to the stimulus under 
DMSO control, with abundance increasing and then decreasing over time (a 
“peak” shape), while others show a less clear response due to signal already 
being present prior to stimulus. For phosphoproteins falling into the former 
category (according to a heuristic), paired t-tests were repeated, but this time 
restricted to intermediate time points within the peak. This focuses on the 
portion of the time course where an inhibition effect, if present, should be seen. 
The p-value from the repeated test was retained if smaller than the original p-
value. For each (cell line, stimulus) context and inhibitor regime, the resulting set 
of p-values (one p-value for each phosphoprotein) were corrected for multiple 
testing using the adaptive linear step-up procedure for controlling the FDR 
(Benjamini et al., 2006).  
  
For each (cell line, stimulus) context, a phosphoprotein was deemed to show a 
salient change under a given inhibitor regime if two conditions were satisfied. 
First, the corresponding FDR value had to be less than 5% and, second, the effect 
size (log2 ratio between DMSO control and inhibitor conditions) had to be 
sufficiently large relative to replicate variation (see Figure S2).  The latter 
condition is an additional filter to remove small effects. Replicate variation was 
quantified by calculating the pooled replicate standard deviation at each time 
point of the DMSO and inhibitor time courses, and then averaging these values 
across time points. The phosphoproteins satisfying these criteria are depicted in 
Figures 3B, 4A, S1, S2 and S3. We note that the overall procedure is heuristic and 
that the FDR values should not be interpreted formally. 
 
A phosphoprotein p showing a salient change under an inhibitor is consistent 
with a node targeted by the inhibitor having a causal effect on the 
phosphoprotein. Since this effect can be direct or indirect, phosphoprotein p can 
be regarded as a descendant of the inhibitor target node in the underlying 
signaling network. That is, there exists a directed path starting from the node 




Networks were learned for each of the 32 (cell line, stimulus) contexts using 
dynamic Bayesian networks (DBNs), a type of probabilistic graphical model for 
time-course data (see e.g. Hill et al., 2012; Husmeier, 2003; Murphy, 2002). 
Specifically we used a recently proposed variant called interventional DBNs or 
iDBNs (Spencer et al., 2015), that uses ideas from causal inference (Pearl, 2009; 
Spirtes et al., 2000) to model interventions and thereby improve ability to infer 
causal relationships; model specification followed Spencer et al. (2015). 
Although interested in learning context-specific networks, we expect a good 
proportion of agreement between contexts. Therefore, rather than learn 
networks for each context separately, we used a recently developed joint 
learning approach to solve all the problem instances together (Oates et al., 
2014). A prior network was used (Figure S4); this was curated manually with 
input from literature (Weinberg, 2013) and online resources. The extent to 
which context-specific networks are encouraged to agree with each other and 
with the prior network is controlled by two parameters, 𝜆 and 𝜂 respectively, as 
described in detail in Oates et al. (2014). These parameters were set (to 𝜆 = 3 
and 𝜂 = 15) by considering a grid of possible values and selecting an option that 
provides a reasonable, but conservative amount of agreement, allowing for 
discovery of context-specific edges that are not in the canonical prior network. 
The network learning approach resulted in a score (edge probability) for each 
possible edge in each context-specific network. The network estimates were 
robust to moderate data deletion and precise specification of the biological prior 
network and its strength (Figure S6). Furthermore, the analyses were 
computationally efficient, requiring approximately 30 minutes to learn all 32 
context-specific networks using serial computation on a standard personal 
computer (Intel i7-2640M 2.80GHz processor, 8GB RAM).  
Assessing Performance of Causal Network Learning 
The ability of our network learning approach to estimate context-specific causal 
networks was systematically assessed using a train and test scheme proposed by 
Hill et al. (2016) in the context of the HPN-DREAM network inference challenge 
associated with the RPPA data presented here. Due to factors specific to the 
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challenge setting, Hill et al. (2016) used only a single iteration of train and test. In 
contrast, we were able to perform several iterations, as described below. 
 
In each iteration, the data were divided into two sets: (i) a test data set, 
consisting of time courses for all 32 (cell line, stimulus) contexts under a single 
inhibitor regime, and (ii) a training data set, consisting of time courses (again for 
all 32 contexts) for a subset of the remaining five inhibitor regimes (Figure S5A). 
We refer to the single inhibitor regime in the test data as the test inhibitor 
(although note that one regime contains more than one kinase inhibitor: 
GSK690693 & GSK1120212).  Thirty-two context-specific networks were learned 
on the training data set and then each network was assessed as to how well it 
agreed with changes observed, for the same context, under the test inhibitor (in 
the test data set). For each test inhibitor, the set of phosphoproteins that show, 
for a given context, a salient change in abundance were determined as described 
above  (and shown in Figures 4A & S3), resulting in context-specific “gold-
standard” descendant sets. We then compared, for each context, predicted 
descendants of the test inhibitor target node(s) according to the network 
inferred from training data, against the corresponding “gold-standard” 
descendant set. This resulted in a number of correctly predicted descendants 
(true positives, TPs) and a number of incorrectly predicted descendants (false 
positives, FPs).  Our network learning approach outputs edge probabilities, from 
which a network can be obtained using a threshold value.  The TP and FP values 
were therefore a function of this threshold value, resulting in an ROC (receiver 
operating characteristic) curve. Our final assessment metric was then the area 
under this curve (AUROC), which we calculated for each context and test 
inhibitor (Figure S5B). The statistical significance of the AUROC scores was 
determined using an empirical null distribution, generated by calculating AUROC 
scores for sets of uniformly random edge probabilities. 
 
The assessment procedure requires that nodes targeted by the test inhibitor are 
present in the network model so that their descendants can be determined. Also, 
it is important that the training data only contains inhibitor regimes that target 
nodes which are not also targeted by the test inhibitor. There were three train 
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and test data splits that satisfied these criteria (while also maximizing the 
sample size of the training data set), and we assessed performance for all three 
(Figure S5B). 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Replicates were averaged prior to carrying out statistical analysis and the time 
courses shown in Figures 3 and S1 were plotted using replicate-averaged data.  
The number of replicates were as follows: ~16 replicates for samples at t = 0, 
except for UACC812, BT20 and MCF7 DMSO t = 0 samples which were replicated 
~32 times; 2 replicates for the majority of DMSO samples at t > 0, except for 
BT20 DMSO samples; all other samples had a single replicate. 
 
Details of statistical procedures are provided in the methods section above or in 
figure legends. Analyses were performed using Matlab R2012a software. 
 
DATA AND SOFTWARE AVAILABILITY 
Software 
Scripts for the computational and statistical analyses presented here are 
available at https://github.com/Steven-M-Hill/causal-signaling-networks-
CellSystems2016. These scripts include identification of changes under kinase 
inhibition, network learning and assessment of network learning performance. 
Data Resources 
RPPA data, including additional time points and antibodies that were not used in 
the analyses presented here, are provided in Data S1. Time-course plots for all of 
the antibodies are provided in Data S2. 
 
ADDITIONAL RESOURCES 
HPN-DREAM network inference challenge associated with the RPPA data 
presented here: https://www.synapse.org/HPN_DREAM_Network_Challenge. 
